Loading
Latest filing published 13 Aug 2024 for Lexaria Bioscience Corp., €4,579.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Catherine C. Turkel across 2 companies, led by Eledon Pharmaceuticals, Inc. and Lexaria Bioscience Corp. Over a trading history stretching from 10 May 2017 to 12 August 2024, the count stands at 10 filings.
Both buying and selling appear: 6 purchases worth €252k, against 2 sales worth €17k. Purchases outweigh sales by €236k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants. 2024 to date brings 1 purchase and no sales.
Half of the purchases are above €36k and half below. Clusters matter here: 1 out of 6 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. After 6 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -40.8%. These figures describe past trades and do not predict future prices.
Most recently, on 13 August 2024, the filings show an open-market purchase worth €4,579 in Lexaria Bioscience Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations